FDA Approval Activities for this Drug…

Zemplar (paricalcitol injection), Abbott NDA 20-819/S7, S11 2/24/03 3/10/03 Zemplar (paricalcitol injection), 5 mcg/mL Abbott NDA 20-819/S-003 2/2/00 2/4/00 2/4/00 Zemplar Indicated: For the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Zemplar (paricalcitol) Injection Abbott NDA 20-819 Zemplar (paricalcitol) Injection, Abbott Laboratories

For the latest approval information, please locate this drug using this index.